SCHEMBL22648191

SCHEMBL22648191

Cc1sncc1-c1ccc(-c2cccc(F)c2)c(N)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.41
FYN P06241 2/20 0.39
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
MAP4K4 O95819 2/20 0.36
CHEK2 O96017 2/20 0.36
TDO2 P48775 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
DCK P27707 1/20 0.36
BACE1 P56817 1/20 0.35
PLK4 O00444 1/20 0.35
CHEK1 O14757 1/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
CDK1 P06493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22648196 0.86 TDO2 (0.51) KDM4EMEN1MAPTKMT2APDE3B
SCHEMBL22637109 0.81 CYP2A6 (0.42) MEN1MAPTPDE3BPDE3ATDO2
SCHEMBL22636776 0.78 FEN1 (0.32) TDO2ALOX5APFEN1
SCHEMBL29430608 0.77 TAAR1 (0.41) TAAR1FYNKDM4EMEN1MAPT
SCHEMBL22636771 0.77 TAAR1 (0.41) TAAR1FYNKDM4EMEN1MAPT
SCHEMBL29430620 0.76 MAPK1 (0.44) TAAR1FYNMEN1MAPTKMT2A
SCHEMBL22636714 0.76 MAPK1 (0.44) TAAR1FYNMEN1MAPTKMT2A
SCHEMBL22648208 0.76 KCNH2 (0.45) KDM4EMEN1KMT2ACHEK2TDO2
SCHEMBL22636632 0.75 ALDH1A1 (0.34) MEN1MAPTKMT2ATDO2DYRK1A
SCHEMBL22636620 0.75 TDO2 (0.39) KDM4EMEN1KMT2ACHEK2TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators Grey Wolf Therapeutics Limited (GB) 2024-07-02 US disclosed
EP-3966196-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-03-16 EP disclosed
WO-2020225569-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12023333-B2 Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators ERAP1, CHP1, QSOX1 TAAR1 2114/4885FYN 2657/4885KDM4E 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.